APYX icon

Apyx Medical

1.58 USD
-0.06
3.66%
Updated Dec 30, 11:06 AM EST
1 day
-3.66%
5 days
-1.86%
1 month
-16.84%
3 months
27.42%
6 months
21.54%
Year to date
-40.82%
1 year
-40.82%
5 years
-81.01%
10 years
-57.98%
 

About: Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.

Employees: 252

0
Funds holding %
of 6,812 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

21,750% more call options, than puts

Call options by funds: $437K | Put options by funds: $2K

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

0.37% less ownership

Funds ownership: 37.23% [Q2] → 36.86% (-0.37%) [Q3]

8% less funds holding

Funds holding: 48 [Q2] → 44 (-4) [Q3]

8% less capital invested

Capital invested by funds: $17.3M [Q2] → $15.8M (-$1.45M) [Q3]

50% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 8

50% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 14

Research analyst outlook

We haven’t received any recent analyst ratings for APYX.

Financial journalist opinion

Neutral
GlobeNewsWire
1 month ago
Apyx Medical Corporation to Attend 15th Annual Craig-Hallum Alpha Select Conference
CLEARWATER, Fla., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that Charles Goodwin, President and CEO and Matt Hill, CFO will be attending the following upcoming conference:
Apyx Medical Corporation to Attend 15th Annual Craig-Hallum Alpha Select Conference
Neutral
Seeking Alpha
1 month ago
Apyx Medical Corporation (APYX) Q3 2024 Earnings Call Transcript
Apyx Medical Corporation (NASDAQ:APYX ) Q3 2024 Earnings Call Transcript November 8, 2024 8:00 AM ET Company Participants Jeremy Feffer - MD, LifeSci Advisors Stavros Vizirgianakis - Executive Chairman Charlie Goodwin - CEO Matt Hill - CFO Conference Call Participants Matthew O'Brien - Piper Sandler Matt Hewitt - Craig-Hallum Capital Group Sam Eiber - BTIG Ben Haynor - Lake Street Capital Markets Operator Ladies and gentlemen, good morning, and welcome to the Apyx Medical Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Apyx Medical Corporation (APYX) Q3 2024 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
Apyx Medical (APYX) Reports Q3 Loss, Lags Revenue Estimates
Apyx Medical (APYX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.13 per share a year ago.
Apyx Medical (APYX) Reports Q3 Loss, Lags Revenue Estimates
Neutral
GlobeNewsWire
1 month ago
Apyx Medical Corporation Announces $7,000,000 Million Registered Direct Offering
CLEARWATER, Fla., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical” or the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced it has entered into a definitive purchase agreement with Nantahala Capital for the purchase and sale in a registered direct offering of 3,000,000 shares of the Company's common stock at a purchase price of $1.18 per share and pre-funded warrants to purchase up to 2,934,690 shares of the Company's common stock at a purchase price of $1.179 per pre-funded warrant (which represents the per share offering price for common stock less the exercise price per share for each pre-funded warrant of $0.001). The gross proceeds to Apyx Medical from the offering were approximately $7,000,000, before deducting offering expenses payable by the Company. The offering closed on November 8, 2024.
Apyx Medical Corporation Announces $7,000,000 Million Registered Direct Offering
Neutral
GlobeNewsWire
1 month ago
Apyx Medical Corporation Reports Third Quarter 2024 Financial Results; Updates Full Year 2024 Financial Outlook and Introduces Full Year 2025 Financial Outlook
CLEARWATER, Fla., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported the financial results for its third quarter ended September 30, 2024, updated its financial expectations for the full year ending December 31, 2024, and introduced its financial expectations for the full year ending December 31, 2025.
Apyx Medical Corporation Reports Third Quarter 2024 Financial Results; Updates Full Year 2024 Financial Outlook and Introduces Full Year 2025 Financial Outlook
Neutral
GlobeNewsWire
2 months ago
Apyx Medical Corporation to Release Third Quarter Of Fiscal Year 2024 Financial Results on November 8, 2024
CLEARWATER, Fla., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Apyx® Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that financial results for the third quarter of fiscal year 2024 will be released before the market opens on Friday, November 8th.
Apyx Medical Corporation to Release Third Quarter Of Fiscal Year 2024 Financial Results on November 8, 2024
Positive
Zacks Investment Research
2 months ago
Apyx (APYX) Upgraded to Buy: Here's What You Should Know
Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Apyx (APYX) Upgraded to Buy: Here's What You Should Know
Neutral
PRNewsWire
4 months ago
Renuvion Named #1 Trusted Body Contouring Technology by Doctors*
Independent survey reveals Renuvion is #1 trusted body contouring technology* with plastic and cosmetic surgeons. CLEARWATER, Fla.
Renuvion Named #1 Trusted Body Contouring Technology by Doctors*
Neutral
Seeking Alpha
4 months ago
Apyx Medical Corporation (APYX) Q2 2024 Earnings Call Transcript
Apyx Medical Corporation (NASDAQ:APYX ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Charles Goodwin - President, Chief Executive Officer & Director Matthew Hill - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Frank Takkinen - Lake Street Capitals George Sellers - Stephens Inc Operator Hello, and welcome, ladies and gentlemen, to the Second Quarter of Fiscal Year 2024 Earnings Conference Call for Apyx Medical Corporation. At this time all participants have been placed in a listen-only more.
Apyx Medical Corporation (APYX) Q2 2024 Earnings Call Transcript
Negative
Zacks Investment Research
4 months ago
Apyx Medical (APYX) Reports Q2 Loss, Lags Revenue Estimates
Apyx Medical (APYX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.11 per share a year ago.
Apyx Medical (APYX) Reports Q2 Loss, Lags Revenue Estimates
Charts implemented using Lightweight Charts™